Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
Rhea-AI Summary
Lifeward (Nasdaq: LFWD) arranged up to $11.2 million in strategic financing through senior secured convertible notes and warrants. An initial $5.6 million closed on July 6, 2026, with another $5.6 million contingent on specific commercial and share-price milestones.
This deal expands access to capital under a broader Oramed-linked framework of up to $47 million, of which $10 million was previously funded, supporting commercialization of Lifeward’s neurorehabilitation platform.
Positive
- Initial $5.6 million financing closed on July 6, 2026
- Total potential new capital from this tranche up to $11.2 million
- Additional $5.6 million tied to 150% ReWalk unit sales growth or $13.80 share price
- Access to up to $47 million total strategic capital framework
- $10 million already funded under the Oramed-linked financing framework
Negative
- Financing structured as senior secured convertible notes, adding debt and potential dilution
- Accompanying warrants further increase potential equity dilution for shareholders
- Second $5.6 million tranche depends on demanding commercial and market-price milestones
Market reaction after growth capital financing: LFWD -3.88% in the Jul 8 session
In the Jul 8 session, LFWD declined 3.88%, reflecting a moderate negative market reaction. Argus tracked a trough of -23.5% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Shareholder letter | Positive | -0.1% | Oramed detailed portfolio gains, loan repayments and index inclusion plans. |
| May 19 | Leadership appointment | Positive | -2.7% | Lifeward appointed a new Chief Medical Officer to support portfolio expansion. |
| May 15 | Q1 2026 earnings | Negative | +1.6% | Revenue fell year over year and margins compressed despite added cash and assets. |
| May 11 | Earnings date notice | Neutral | +1.6% | Company scheduled its Q1 2026 earnings release and investor call. |
| May 04 | Clinical data update | Positive | -2.4% | ReWalk exoskeleton safety data showed low and improving fracture prevalence. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Lifeward headlines have often been positive or strategic while the stock’s next-day moves frequently diverged from the news tone.
Key Terms
securities purchase agreement financial
senior secured convertible notes financial
warrants financial
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial
HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchase agreement with a group of institutional and accredited investors participating in the strategic financing framework established earlier this year with Oramed Pharmaceuticals (Nasdaq: ORMP).
"This financing reflects confidence in our strategy and the opportunity ahead," said Mark Grant, President and Chief Executive Officer of Lifeward. "We have built the clinical evidence, reimbursement infrastructure and commercial foundation needed to scale our business. This additional capital strengthens our ability to accelerate the commercialization of our restorative healthcare platform, including expansion of our reimbursement-backed distribution model, and advancement of our product portfolio.”
The initial closing, which took place on July 6, 2026, consists of approximately
- a
150% increase in ReWalk® unit sales, as reported quarterly, over the trailing twelve-month period; or - Lifeward's ordinary shares trading at or above
$13.80 per share for ten consecutive trading days.
The milestone-based structure aligns additional capital with commercial execution and shareholder value creation. This financing is in addition to, and expands upon, the strategic capital framework established through Lifeward's partnership with Oramed, which provides the Company with access to up to
Additional information regarding the financing is included in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
About Lifeward
Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market.
Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: management’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; Lifeward’s ability to successfully integrate Oratech Pharmaceuticals Ltd. into its organization and realize the anticipated benefits therefrom; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the strategic transaction; expected timing and results of the ORMD-0801 clinical trial; legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company’s ability to continue to operate as a going concern; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Contact:
Almog Adar
Chief Financial Officer
Lifeward
E: media@golifeward.com
E: ir@golifeward.com
